• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国志愿者口服罗苏伐他汀后的单剂量与多剂量比较药代动力学研究。

Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers.

作者信息

Li Yunxia, Jiang Xuehua, Lan Ke, Jiang Qian

机构信息

West China School of Pharmacy, Sichuan University, 610041, Sichuan, China.

出版信息

Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34(3-4):221-7. doi: 10.1007/BF03191177.

DOI:10.1007/BF03191177
PMID:20166442
Abstract

The objective of this study was to determine and compare the plasma concentrations of rosuvastatin following single- and multiple-dose administration in Chinese volunteers. The study was of an open label, randomized, three-way cross-over design and was conducted in 12 subjects. Single dose administration of the rosuvastatinon was characterized by a rapid absorption (2.045 +/- 0.891 h, 2.273 +/- 1.009 h and 1.667 +/- 0.651 h) and a marked peak plasma concentration (9.938 +/- 4.438, 28.09 +/- 12.075 and 43.092 +/- 22.09 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin. The apparent elimination half-life amounted to 7.914 +/- 3.813 h, 8.445 +/- 4.994 h and 15.401 +/- 5.429 h following administration, respectively. Similar findings were obtained after multiple dosing. A rapid absorption (3 +/- 1.365 h, 3.042 +/- 1.054 h and 2.375 +/- 0.829 h) and a marked peak plasma concentration (9.288 +/- 5.314, 18.808 +/- 6.687 and 49.808 +/- 23.516 ng/ml) for the three different doses (5 mg, 10 mg and 20 mg) of rosuvastatin were observed. The apparent elimination half-life amounted to 13.181 +/- 5.492 h, 8.035 +/- 3.331 h and 15.509 +/- 6.43 h following administration, respectively. Small differences in gender are not considered clinically relevant, and dose adjustments based on gender are not anticipated. But the state of fed or fasting will affect the pharmacokinetic of rosuvastatin.

摘要

本研究的目的是测定并比较瑞舒伐他汀在中国志愿者单剂量和多剂量给药后的血浆浓度。该研究采用开放标签、随机、三交叉设计,共纳入12名受试者。单剂量服用瑞舒伐他汀时,三种不同剂量(5毫克、10毫克和20毫克)的瑞舒伐他汀均呈现快速吸收(分别为2.045±0.891小时、2.273±1.009小时和1.667±0.651小时)和显著的血浆峰浓度(分别为9.938±4.438、28.09±12.075和43.092±22.09纳克/毫升)。给药后表观消除半衰期分别为7.914±3.813小时、8.445±4.994小时和15.401±5.429小时。多次给药后也得到了类似的结果。观察到三种不同剂量(5毫克、10毫克和20毫克)的瑞舒伐他汀呈现快速吸收(分别为3±1.365小时、3.042±1.054小时和2.375±0.829小时)和显著的血浆峰浓度(分别为9.288±5.314、18.808±6.687和49.808±23.516纳克/毫升)。给药后表观消除半衰期分别为13.181±5.492小时、8.035±3.331小时和15.509±6.43小时。性别上的微小差异在临床上不被认为具有相关性,预计也无需根据性别调整剂量。但是进食或禁食状态会影响瑞舒伐他汀的药代动力学。

相似文献

1
Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers.中国志愿者口服罗苏伐他汀后的单剂量与多剂量比较药代动力学研究。
Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34(3-4):221-7. doi: 10.1007/BF03191177.
2
Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.罗苏伐他汀在中国志愿者单剂量口服给药后的药代动力学特性:一项随机、开放标签、三交叉研究。
Clin Ther. 2007 Oct;29(10):2194-203. doi: 10.1016/j.clinthera.2007.10.005.
3
Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.在中国居住的健康中国志愿者中瑞舒伐他汀的药代动力学:一项随机、开放标签、递增单剂量和多剂量研究。
Clin Ther. 2010 Mar;32(3):575-87. doi: 10.1016/j.clinthera.2010.03.015.
4
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.一项双盲、随机、不完全交叉试验,旨在评估健康志愿者中瑞舒伐他汀的剂量比例关系。
Clin Ther. 2003 Aug;25(8):2215-24. doi: 10.1016/s0149-2918(03)80214-x.
5
Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.新型HMG-CoA还原酶抑制剂瑞舒伐他汀在健康志愿者中晨服或晚服后的药效学效应及药代动力学
Br J Clin Pharmacol. 2002 Nov;54(5):472-7. doi: 10.1046/j.1365-2125.2002.01688.x.
6
Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.健康成年白人男性志愿者中瑞舒伐他汀的绝对口服生物利用度。
Clin Ther. 2003 Oct;25(10):2553-63. doi: 10.1016/s0149-2918(03)80316-8.
7
ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.ABCB1基因多态性、ABCB1单倍型以及ABCG2 c.421C>A是瑞舒伐他汀药代动力学个体间变异性的决定因素。
Pharmazie. 2013 Feb;68(2):129-34.
8
Effect of food on the pharmacokinetics of rosuvastatin after administration of a single oral dose in dogs.
Drug Res (Stuttg). 2013 Mar;63(3):145-9. doi: 10.1055/s-0033-1333736. Epub 2013 Feb 11.
9
Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.接受包括环孢素在内的抗排斥治疗方案的心脏移植受者中瑞舒伐他汀的药代动力学。
Clin Pharmacol Ther. 2004 Aug;76(2):167-77. doi: 10.1016/j.clpt.2004.03.010.
10
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.吉非贝齐对瑞舒伐他汀药代动力学的影响。
Clin Pharmacol Ther. 2004 May;75(5):455-63. doi: 10.1016/j.clpt.2003.12.014.

引用本文的文献

1
Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.健康高加索人群单次及多次给药后替米沙坦与瑞舒伐他汀之间药物相互作用的评估。
Drug Des Devel Ther. 2018 Apr 6;12:787-794. doi: 10.2147/DDDT.S145339. eCollection 2018.

本文引用的文献

1
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.居住在同一环境中的白种人和亚洲受试者中瑞舒伐他汀的药代动力学和药物遗传学。
Clin Pharmacol Ther. 2005 Oct;78(4):330-41. doi: 10.1016/j.clpt.2005.06.013.
2
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.吉非贝齐对瑞舒伐他汀药代动力学的影响。
Clin Pharmacol Ther. 2004 May;75(5):455-63. doi: 10.1016/j.clpt.2003.12.014.
3
Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.
Drug Metab Dispos. 2002 Nov;30(11):1158-63. doi: 10.1124/dmd.30.11.1158.
4
No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.年龄和性别对新型HMG-CoA还原酶抑制剂瑞舒伐他汀的药代动力学无影响。
J Clin Pharmacol. 2002 Oct;42(10):1116-21. doi: 10.1177/009127002401382722.